Iovance’s lifileucel shows responses in 50% of eight patients with advanced sarcomas
The therapy showed responses in 50% of eight patients in a pilot study of advanced sarcomas.
The therapy showed responses in 50% of eight patients in a pilot study of advanced sarcomas.